Modelling and simulation to improve decision-making in clinical development

Pharmaceutical Statistics

Volumn 4, Issue 1, 2005, Pages 47-58

  Burman, Carl Fredrik ^a   Hamrén, Bengt ^a   Olsson, Per ^b  

^a ASTRAZENECA R AND D   (Sweden)

^b Exprimo Consulting LLP   (United Kingdom)

Author keywords

Clinical trial simulation; Decision analysis; Modelling; Optimal design; PK PD

Indexed keywords

AREA UNDER THE CURVE; ARTICLE; CLINICAL RESEARCH; DECISION MAKING; DECISION THEORY; DOSE RESPONSE; DRUG INFORMATION; DRUG RESEARCH; MEDICAL INFORMATION; MODEL; PHARMACODYNAMICS; PREDICTION; PROCESS OPTIMIZATION; SIMULATION; STANDARDIZATION; STATISTICAL ANALYSIS; TIME; TREATMENT OUTCOME;

EID: 15844380596     PISSN: 15391604     EISSN: None     Source Type: Journal    
DOI: 10.1002/pst.153     Document Type: Article

References (35)

1. Gobburu JVS, Marroum PJ. Utilisation of pharmacokinetic-pharmacodynamic modelling and simulation in regulatory decision-making. Clinical Pharmacokinetics 2001; 40:863-892.
2. McPearson G. In Silly Co. SPIN, the PSI Newsletter 2002(Autumn):9.
3. Holford NHG, Kimko HC, Monteleone JPR, Peck CC. Simulation of clinical trials. Annual Review of Pharmacology & Toxicology 2000; 40:209-234.
4. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, Wastall P. The prediction of human pharmacokinetic parameters from preclinical and in vitro data. Journal of Pharmacology and Experimental Therapeutics 1997; 283:46-58.
5. Gomeni R, Bani M, D'Angeli C, Bye A. Computer-assisted drug development (CADD): an emerging technology for designing first-time-in-man and proof-of-concept studies from preclinical experiments. European Journal of Pharmaceutical Sciences 2001; 13:261-270.
6. Box GEP, Hunter WG, Hunter JS. Statistics for experimenters. An introduction to design, data analysis and model building. Wiley: New York, 1978.
7. Hoppensteadt FC, Peskin CS. Modeling and simulation in medicine and the life sciences, 2nd edition. Springer: New York, 2002.
8. Friberg LE, Karlsson MO. Mechanistic models for myelosuppression. Investigational New Drugs 2003; 21:183-194.
9. Boxenbaum H. Pharmacokinetics: philosophy of modeling. Drug Metabolism Reviews 1992; 24: 89-120.
10. Parmigiani G. Modeling in medical decision making: a Bayesian approach. Wiley: Chichester, 2002.
11. Gelman A, Carlin JB, Stern S, Rubin RB. Bayesian data analysis. Chapman & Hall: London, 1995.
12. Holford NHG, Hale M, Ko HC, Steimer J-L, Sheiner LB, Peck CC. Simulation in drug development: good practices. CDDS, Georgtown University, 1999. http://www.cdds.georgetown.edu/SDDGP.html (accessed August 2004).
13. Ross SM. Simulation, 2nd edition. Academic Press: San Diego, CA, 1997.
14. Raiffa H. Decision analysis. Introductory lectures on choices under uncertainty. McGraw-Hill: New York, 1997 (reprint).
15. Bather J. Decision theory. An introduction to dynamic programming and sequential decisions. Wiley: Chichester, 2000.
16. Box GEP. Science and statistics. Journal of the American Statistical Association 1976; 71:791-799.
17. Chan PL, Holford NH. Drug treatment effects on disease progression. Annual Review of Pharmacology & Toxicology 2001; 41 625-659.
18. Atkinson AC, Donev AN. Optimum experimental design. Oxford University Press: New York, 1992.
19. Gabrielsson J, Weiner D. Pharmacokinetic and pharmacodynamic data analysis: concepts and applications, 3rd edition. Swedish Pharmaceutical Press: Stockholm, 1997.
20. Guidance for industry. Exposure-response relationships - study design, data analysis, and regulatory applications. FDA, 2003. http://www/fda.gov/cber/gdlns/exposure.htm (accessed December 2004).
21. Derendorf H, Lesko LJ, Chaikin P, Colburn WA, Lee P, Miller R, Powell R, Rhodes G, Stanski D, Venitz J. Pharmacokinetic-pharmacodynamic modeling in drug research and development. Journal of Clinical Pharmacology 2000; 40 1399-1418.
22. Lesko LJ, Rowland M, Peck CC, Blaschke TF. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Pharmaceutical Research 2000; 17:1335-1344.
23. Sheiner LB, Steimer J-L. Pharmacokinetic/pharmacodynamic modeling in drug development. Annual Review of Pharmacology & Toxicology 2000; 40: 67-95.
24. Kowalski KG, Hutmacher MH. Design evaluation for a population pharmacokinetic study using clinical trial simulation: a case study. Statistics in Medicine 2001; 20:75-91.
25. Jusko WJ, Ko HC. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clinical Pharmacology & Therapeutics 1995; 56:406-419.
26. Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications, 3rd edition. Williams and Wilkins: Baltimore, MD, 1995.
27. Fleming TR, Harrington DP. Counting processes and survival analysis. Wiley: New York, 1991; Chapter 7.
28. Gebski V, McNeil D, Coates A, Forbes J. Monitoring distributional assumptions and early stopping for a prospective clinical trial using Monte Carlo simulation. Statistics in Medicine 1987; 6:667-678.
29. Pezeshk H. Bayesian techniques for sample size determination in clinical trials: a short review. Statistical Methods in Medical Research 2003; 12:489-504.
30. Poland B, Wada R. Combining drug-disease and economic modelling to inform drug development decisions. Drug Discovery Today 2001; 6:1165-1170.
31. Pallay A, Berry S. A decision analysis for an end of phase II go/stop decision. Drug Information Journal 1999; 33:821-833.
32. Peck CC, Rubin DB, Sheiner LB. Hypothesis: A single clinical trial plus causal evidence of effectiveness is sufficient for drug approval. Clinical Pharmacology & Therapeutics 2003; 73 481-490.
33. Gooley TA, Martin PJ, Fisher LD, Pettinger M. Simulation as a design tool for phase I-II clinical trials: an example from bone marrow transplantation. Controlled Clinical Trials 1994; 15:450-462.
34. Kimko HC, Reele SSB, Holford NHG, Peck CC. Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model. Clinical Pharmacology & Therapeutics 2000; 68:568-577.
35. Nani F, Oguztoreli M. Modelling and simulation of chemotherapy of haematological and gynaecological cancers. IMA Journal of Mathematics Applied in Medicine and Biology 1999; 16:39-91.